aTyr Pharma

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

aTyr Pharma (LIFE) reports robust Q4 earnings, advances lead candidate

aTyr Pharma (LIFE) is well-positioned with a strong financial standing, a focus on innovative drug development for inflammatory diseases, and ongoing clinical trials for lead candidate efzofitimod targeting ILD and pulmonary sarcoidosis. While facing challenges in addressing analyst inquiries, the company has opportunities to advance its pipeline and leverage its financial resources for future growth.

aTyr Pharma progresses efzofitimod for ILD treatment, eyes transformative growth

aTyr Pharma's strong performance in advancing efzofitimod, solid financial position, and focus on innovation position them well for future growth and success
While facing challenges in pivotal studies and program management, the company's opportunities in pipeline expansion and disruptive drug discovery set a positive trajectory

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pangu's basic and translational research in tRNA synthetase biology, conducted in collaboration with the Hong Kong University of Science and Technology, contributed to successful clinical proof-of-concept findings.

aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Positive Data from a Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response of ATYR1923 in Pulmonary Sarcoidosis

Investors need to pay close attention to aTyr Pharma (LIFE) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in aTyr Pharma (LIFE) Stock?

aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q2 2021 Results - Earnings Call Transcript

Shares of aTyr Pharma (NASDAQ:LIFE) fell in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 7.25% over the past year to ($0.64), which missed the estimate of ($0.51).

aTyr Pharma: Q2 Earnings Insights

Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in mid-September 2021.

aTyr Pharma Announces Second Quarter 2021 Results and Provides Corporate Update

LOS ANGELES--(BUSINESS WIRE)---- $LIFE #CapitalCommitment--Russian listed pharmaceutical manufacturer, Pharmsynthez PJSC (MOEX:LIFE), secures 800 million rubles from global alternative investor, LDA Capital

Pharmsynthez PJSC Secures RUB 800m With LDA Capital

Event will feature Dr. Daniel Culver, Director of the Interstitial Lung Disease Program at the Cleveland Clinic.

aTyr Pharma to Host Virtual Key Opinion Leader Event on Current Treatment Options for Pulmonary Sarcoidosis

Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of antibodies targeting NRP2.

aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody

BioNTech SE

Connect Biopharma Holdings

Fulgent Genetics

GlaxoSmithKline

Knnate Biopharma

Karyopharm Therapeutics

Legend Biotech

Eli Lilly

Genscript raised more than $1 billion from Hillhouse Capital in several different investments, including a $500 million commitment to Genscript's Legend Biotech CAR-T subsidiary. Shanghai Fosun Pharma formed a JV with its COVID-19 partner BioNTech to manufacture their partnered mRNA vaccine in China.

Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse

aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q1 2021 Results - Earnings Call Transcript

Atyr Pharma (LIFE) delivered earnings and revenue surprises of -50.00% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Atyr Pharma (LIFE) Reports Q1 Loss, Lags Revenue Estimates

Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in the third quarter.

aTyr Pharma Announces First Quarter 2021 Results and Provides Corporate Update

Atyr Pharma (LIFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Atyr Pharma (LIFE) to Report a Decline in Earnings: What to Look Out for

Panel discussion on steroids and sarcoidosis to be held on Tuesday, April 27 at 12:00pm ET / 3:00pm PT Panel discussion on steroids and sarcoidosis to be held on Tuesday, April 27 at 12:00pm ET / 3:00pm PT

aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Steroids and Sarcoidosis

Lonza Group AG

aTyr Pharma Inc (NASDAQ: LIFE) and Lonza Group Ltd (OTCMKTS: LZAGF) have agreed to manufacture ATYR2810, aTyr's monoclonal antibody targeting Neuropilin-2 (NRP2) that is currently in preclinical development for cancer. Under the terms of the agreement, Lonza will utilize its Ibex Design to manufacture material for ATYR2810.

aTyr Pharma Recruits Lonza As Manufacturing Partner For Cancer Therapy ATYR2810

Findings demonstrate tumor inhibitory effects of ATYR2810 when used as a monotherapy or in combination with chemotherapy in models of non-small cell lung cancer.

aTyr Pharma Presents Preclinical Research Showing Effects of ATYR2810 in Lung and Breast Cancer at the 2021 AACR Virtual Annual Meeting

aTyr Pharma, Inc. (LIFE) CEO Dr. Sanjay Shukla on Q4 2020 Results - Earnings Call Transcript

Shares of aTyr Pharma (NASDAQ:LIFE) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 69.48% over the past year to ($0.47), which beat the estimate of ($0.82).

aTyr Pharma: Q4 Earnings Insights

Completed enrollment of ATYR1923 clinical trial in patients with pulmonary sarcoidosis. Data is expected in the third quarter.

aTyr Pharma Announces Fourth Quarter and Full Year 2020 Results and Provides Corporate Update

Atyr Pharma (LIFE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Atyr Pharma (LIFE) Moves 26.3% Higher: Will This Strength Last?

Atyr Pharma (LIFE) stock is taking off on Tuesday after getting a price target update from Roth Capital analyst Zegbeh Jallah. The post LIFE Stock: Increased Price Target Gives aTyr Pharma Shares a Big Lift appeared first on InvestorPlace.

LIFE Stock: Increased Price Target Gives aTyr Pharma Shares a Big Lift

ANGI Homeservices

Anaplan Inc

Smartsheet

SVMK Inc

Tradeweb Markets

Twitter

These seven names have shown important insider trading signals after their rallies, meaning some insiders are taking profits in these stocks. The post 7 Stocks With Important Insider Trading Signals That Say Sell appeared first on InvestorPlace.

7 Stocks With Important Insider Trading Signals That Say Sell

aTyr Pharma Inc (NASDAQ: LIFE) has initiated two discovery programs from its tRNA synthetase platform that will investigate the functionality of selected fragments of Alanyl-tRNA Synthetase (AARS) and Aspartyl-tRNA Synthetase (DARS) in immunology, fibrosis, and cancer. The announcement comes after the company published a poster at the 2021 Society for Laboratory Automation and Screening Digital International Conference and Exhibition (SLAS) demonstrating that these extracellular tRNA synthetase fragments bind to innate and adaptive immune cells, including natural killer (NK) cells.

aTyr Pharma Gains On New Programs From tRNA Synthetase Platform For Cancer Targets

Advancement of selected AARS and DARS fragments primarily targeting cancer

aTyr Pharma Announces New tRNA Synthetase Discovery Programs

SAN DIEGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the BIO CEO & Investor Digital Conference, which is being held February 16 – 18, 2021.

News for aTyr Pharma Stock (LIFE)